Yoshihiro Kawasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshihiro Kawasaki has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Tetsu Akiyama
Laboratory of Molecular and Genetic Information, Institute for Quantitative Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan
5 shared publications Sakiko Suda
Laboratory of Molecular and Genetic Information, Institute for Quantitative Biosciences, The University of Tokyo, Bunkyo-ku, Japan
4 shared publicationsKosuke Matsumura
Laboratory of Molecular and Genetic Information Institute for Quantitative Biosciences The University of Tokyo Bunkyo‐ku Tokyo Japan
3 shared publicationsJoji Kitayama
Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
2 shared publications- Katsuhiko Shirahige
Laboratory of Genome Structure and Function, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan
2 shared publications - Lumi Negishi
Laboratory of Chromatin Structure and Function, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (42) , 4522-4532
The GSEC-encoded polypeptide GESP drives colorectal cancer tumorigenesis via NPM1-c-Myc-mediated repression of NDRG1
Expression of long non-coding RNAs (lncRNAs) is frequently dysregulated in human cancers. We previously reported that the lncRNA GSEC accelerates colorectal cancer (CRC) cell motility by inhibiting the RNA helicase DHX36. Here, we demonstrated that a nuclear polypeptide (designated ‘GESP’) is translated from a short ORF encoded by GSEC, which is highly expressed in CRC cells. In vivo experiments using CRC cell-xenografted mice revealed that GESP is required for development of immature tumors through suppression of a critical differentiation factor, NDRG1. Suppression of GESP by shRNA-mediated knockdown of GSEC caused growth retardation associated with tumor differentiation. At the molecular level, GESP recruits c-Myc to the promoter region of NDRG1 by forming a GESP-NPM1-c-Myc complex, which consequently represses transcription of NDRG1. Collectively, these data indicate a novel lncRNA product, GESP, plays a pivotal role in CRC tumor development/progression by suppression of tumor cell differentiation through the GESP-NDRG1 axis.
- 1 September 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (42) , 4522-4532
Open AccessThe GSEC-encoded polypeptide GESP drives colorectal cancer tumorigenesis via NPM1-c-Myc-mediated repression of NDRG1
Expression of long non-coding RNAs (lncRNAs) is frequently dysregulated in human cancers. We previously reported that the lncRNA GSEC accelerates colorectal cancer (CRC) cell motility by inhibiting the RNA helicase DHX36. Here, we demonstrated that a nuclear polypeptide (designated ‘GESP’) is translated from a short ORF encoded by GSEC, which is highly expressed in CRC cells. In vivo experiments using CRC cell-xenografted mice revealed that GESP is required for development of immature tumors through suppression of a critical differentiation factor, NDRG1. Suppression of GESP by shRNA-mediated knockdown of GSEC caused growth retardation associated with tumor differentiation. At the molecular level, GESP recruits c-Myc to the promoter region of NDRG1 by forming a GESP-NPM1-c-Myc complex, which consequently represses transcription of NDRG1. Collectively, these data indicate a novel lncRNA product, GESP, plays a pivotal role in CRC tumor development/progression by suppression of tumor cell differentiation through the GESP-NDRG1 axis.
- Open Access
- 29 July 2019
- Published by Springer Nature in EMBO Reports
- Vol. 20 (8) , e47052
The novel lncRNA CALIC upregulates AXL to promote colon cancer metastasis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 29 July 2019
- Published by Springer Nature in EMBO Reports
- Vol. 20 (8) , e47052
Open AccessThe novel lncRNA CALIC upregulates AXL to promote colon cancer metastasis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
- 1 September 2016
- Published by Elsevier in Cell Reports
- Vol. 16 (10) , 2554-2564
MYU, a Target lncRNA for Wnt/c-Myc Signaling, Mediates Induction of CDK6 to Promote Cell Cycle Progression
- 1 September 2016
- Published by Elsevier in Cell Reports
- Vol. 16 (10) , 2554-2564
Open AccessMYU, a Target lncRNA for Wnt/c-Myc Signaling, Mediates Induction of CDK6 to Promote Cell Cycle Progression
- Open Access
- 21 September 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 14291
REG4 is a transcriptional target of GATA6 and is essential for colorectal tumorigenesis
The transcription factor GATA6 is a critical regulator of cell proliferation and development in the gastrointestinal tract. We have recently reported that GATA6 induces the expression of the intestinal stem cell marker LGR5 and enhances the clonogenicity and tumorigenicity of colon cancer cells, but not the growth of these cells cultured under adherent conditions. Here we show that REG4, a member of the regenerating islet-derived (REG) family, is also a target of GATA6. We further demonstrate that REG4 is downregulated by overexpression of miR-363, which suppresses GATA6 expression. Moreover, we show that GATA6-mediated activation of REG4 enhances the growth of colon cancer cells under adherent conditions and is required for their tumorigenicity. Taken together, our findings demonstrate that GATA6 simultaneously induces the expression of genes essential for the growth of colon cancer cells under adherent conditions (REG4) and genes required for their clonogenicity (LGR5) and that the miR-363-GATA6-REG4/LGR5 signaling cascade promotes the tumorigenicity of colon cancer cells.
- 21 September 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 14291
Open AccessREG4 is a transcriptional target of GATA6 and is essential for colorectal tumorigenesis
The transcription factor GATA6 is a critical regulator of cell proliferation and development in the gastrointestinal tract. We have recently reported that GATA6 induces the expression of the intestinal stem cell marker LGR5 and enhances the clonogenicity and tumorigenicity of colon cancer cells, but not the growth of these cells cultured under adherent conditions. Here we show that REG4, a member of the regenerating islet-derived (REG) family, is also a target of GATA6. We further demonstrate that REG4 is downregulated by overexpression of miR-363, which suppresses GATA6 expression. Moreover, we show that GATA6-mediated activation of REG4 enhances the growth of colon cancer cells under adherent conditions and is required for their tumorigenicity. Taken together, our findings demonstrate that GATA6 simultaneously induces the expression of genes essential for the growth of colon cancer cells under adherent conditions (REG4) and genes required for their clonogenicity (LGR5) and that the miR-363-GATA6-REG4/LGR5 signaling cascade promotes the tumorigenicity of colon cancer cells.
- 1 August 2015
- Vol. 73 (8) , 1283-7
[Tumor microenvironment: promising therapeutic target].
Tumors are complex tissues composed of cancer cells, various types of stromal cells and extracellular matrix. Recent studies have shown that the tumor microenvironment(TME) plays an important role in both malignant tumor progression and treatment response. Thus, it is essential to improve our understanding of the mechanism of communication between cancer cells and their TME. Much effort has been devoted to developing agents that interfere with the interaction between cancer cells and their TME. In this review, we show a brief overview over the current knowledge about the TME-targeting agents and describe therapeutic strategies that have been designed to target components of the TME.
- 1 August 2015
- Vol. 73 (8) , 1283-7
[Tumor microenvironment: promising therapeutic target].
Tumors are complex tissues composed of cancer cells, various types of stromal cells and extracellular matrix. Recent studies have shown that the tumor microenvironment(TME) plays an important role in both malignant tumor progression and treatment response. Thus, it is essential to improve our understanding of the mechanism of communication between cancer cells and their TME. Much effort has been devoted to developing agents that interfere with the interaction between cancer cells and their TME. In this review, we show a brief overview over the current knowledge about the TME-targeting agents and describe therapeutic strategies that have been designed to target components of the TME.
- 1 January 1992
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 56 (3) , 441-444
Characteristics of Chymotrypsin Modified with Water-soluble Acylating Reagents and Its Peptide Synthesis Ability in Aqueous Organic Media
Several kinds of modified chymotrypsin were prepared with water-soluble acylating reagents, and their characteristics after hydrolyzing with unmodified chymotrypsin in aqueous-N,N'-dimethylformamide (DMF) media were compared. It was found that chymotrypsin (Csin), of which a 20% amino group was modified with a benzyloxycarbonyl group (Z(20)Csin), had more favorable characteristics than unmodified chymotrypsin with regard to hydrolytic activity in an aqueous DMF media. We also investigated the Z(20)Csin-catalyzed peptide synthesis in two different solution systems. In the one-layer system containing water and DMF, Z(20)Csin catalyzed the peptide bond formation in a higher yield than that by unmodifide chymotrypsin and enabled a synthetic reaction in even an 80% (v/v) DMF media, in which the hydrolytic reaction could not be carried out. Z(20)Csin catalyzed the condensation between some N-acyl amino acids or peptide derivatives and amino acids in 90% ethylacetate, 90% hexane or 50% benzene. This latter method employs a two-layer system, and the modified enzyme may be able to reduce the number of synthetic steps when preparing acyl peptides.
- 1 January 1992
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 56 (3) , 441-444
Characteristics of Chymotrypsin Modified with Water-soluble Acylating Reagents and Its Peptide Synthesis Ability in Aqueous Organic Media
Several kinds of modified chymotrypsin were prepared with water-soluble acylating reagents, and their characteristics after hydrolyzing with unmodified chymotrypsin in aqueous-N,N'-dimethylformamide (DMF) media were compared. It was found that chymotrypsin (Csin), of which a 20% amino group was modified with a benzyloxycarbonyl group (Z(20)Csin), had more favorable characteristics than unmodified chymotrypsin with regard to hydrolytic activity in an aqueous DMF media. We also investigated the Z(20)Csin-catalyzed peptide synthesis in two different solution systems. In the one-layer system containing water and DMF, Z(20)Csin catalyzed the peptide bond formation in a higher yield than that by unmodifide chymotrypsin and enabled a synthetic reaction in even an 80% (v/v) DMF media, in which the hydrolytic reaction could not be carried out. Z(20)Csin catalyzed the condensation between some N-acyl amino acids or peptide derivatives and amino acids in 90% ethylacetate, 90% hexane or 50% benzene. This latter method employs a two-layer system, and the modified enzyme may be able to reduce the number of synthetic steps when preparing acyl peptides.
- 1 January 1992
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 56 (1) , 140-141
Large-scale Preparation ofκ-Casein Glycomacropeptide from Rennet Casein Whey
- 1 January 1992
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 56 (1) , 140-141
Large-scale Preparation ofκ-Casein Glycomacropeptide from Rennet Casein Whey